I-Ruxolitinib yi-molecule encinci i-Janus kinase inhibitor esetyenziselwa unyango lwe-myelofibrosis ephakathi okanye ephezulu kunye ne-resistant form of polycythemia vera kunye ne-graft-vs-host disease. I-Ruxolitinib inxulunyaniswa nokunyuka okwethutyana kwaye okuqhelekileyo kwi-serum aminotransferase ngexesha lonyango kunye neemeko ezinqabileyo zokulimala okubonakalayo, okubonakalayo kwekliniki ye-idiosyncratic acute yesibindi kunye neemeko zokuphinda kusebenze i-hepatitis B kubantu abasesichengeni.

I-Ruxolitinib yinto yomlomo ye-bioavailable ye-Janus-associated kinase (JAK) inhibitor ene-antineoplastic kunye nemisebenzi ye-immunomodulating. I-Ruxolitinib ibophelela ngokukodwa kwaye inqanda iprothenityrosinekinases JAK 1 kunye ne-2, enokuthi iholele ekunciphiseni ukuvuvukala kunye nokuthintela ukwanda kwamaselula. I-JAK-STAT (i-transducer yesignali kunye ne-activator ye-transcription) indlela idlala indima ebalulekileyo ekubonakalisweni kwee-cytokines ezininzi kunye nezinto ezikhulayo kwaye zibandakanyeka ekwandeni kwamaselula, ukukhula, i-hematopoiesis, kunye ne-immune response; I-JAK kinases inokulawulwa kwizifo ezivuthayo, ukuphazamiseka kwe-myeloproliferative, kunye neentlobo ezahlukeneyo ezimbi.

IRuxolitinib yiipyrazoleifakwe kwindawo ye-1 ngeqela le-2-cyano-1-cyclopentylethyl kunye ne-3 yeqela le-pyrrolo [2,3-d] pyrimidin-4-yl. Isetyenziswe njengetyuwa ye-phosphate kunyango lwezigulane ezine-myelofibrosis ephakathi okanye ephezulu, kuquka i-myelofibrosis ephantsi, i-post-polycythemia vera myelofibrosis kunye ne-post-essential thrombocythemia myelofibrosis. Inendima njenge-arhente ye-antineoplastic kunye ne-EC 2.7.10.2 (iprotheyini engeyodwa-tyrosinekinase) inhibitor. Yinitrile, apyrrolopyrimidinekunye nelungu lepyrazoles.